Literature DB >> 2224791

Impaired production of tumor necrosis factor in breast cancer.

C C Zielinski1, C Mueller, E Tyl, E Tichatschek, E Kubista, J Spona.   

Abstract

Spontaneous and lipopolysaccharide (LPS)-induced production of tumor necrosis factor (TNF) by peripheral blood macrophages was investigated in breast cancer. Whereas spontaneous TNF production by macrophages derived from patients with breast cancer was comparable with the one found in healthy controls (P greater than 0.1), LPS-stimulated macrophages derived from patients in the disease-free interval as well as with metastatic breast cancer were found to produce significantly lower amounts of TNF, as compared with macrophages derived from healthy control individuals (P less than 0.0005). However, the production of TNF did not significantly differ between the two patient populations (P greater than 0.05). The impairment of LPS-induced TNF production did not depend upon such characteristics of the primary tumor as size, axillary lymph node and estrogen receptor status, or upon the fact of administration of adjuvant chemotherapy and, in patients with metastatic disease, hormone treatment. To further investigate cytokine production by macrophages, spontaneous and LPS-induced interleukin-1 (IL-1) production was investigated also. However, no difference was found between patients and controls concerning IL-1 generation. The authors thus conclude that LPS-induced TNF production was impaired in breast cancer independent of the presence of detectable metastatic disease, whereas IL-1 production remained unimpaired.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2224791     DOI: 10.1002/1097-0142(19901101)66:9<1944::aid-cncr2820660916>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  TNF-alpha levels in cancer patients relate to social variables.

Authors:  Phillip T Marucha; Timothy R Crespin; Rebecca A Shelby; Barbara L Andersen
Journal:  Brain Behav Immun       Date:  2005-11       Impact factor: 7.217

2.  Impaired cytokine production in whole blood cell cultures of patients with urological carcinomas.

Authors:  U Elsässer-Beile; S von Kleist; R Fischer; M Martin; U Wetterauer; H Gallati; J S Mönting
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

3.  Cytokine production in whole blood cell cultures of patients undergoing therapy with biological response modifiers or 5-fluorouracil.

Authors:  U Elsässer-Beile; S von Kleist; A Lindenthal; R Birken; H Gallati; J S Mönting
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

4.  Production of interleukin-1 and tumour necrosis factor in non-Hodgkin's lymphoma patients.

Authors:  K Jhaver; A De; S Advani; J Nadkarni
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Immune defects in breast cancer patients after radiotherapy.

Authors:  Leanna J Standish; Carolyn Torkelson; Frank A Hamill; Daesong Yim; Alicia Hill-Force; Annette Fitzpatrick; Monica Olsen; Sandi Schildt; Erin Sweet; Cynthia A Wenner; Mark R Martzen
Journal:  J Soc Integr Oncol       Date:  2008

6.  TNFSF15 Modulates Neovascularization and Inflammation.

Authors:  Zhisong Zhang; Lu-Yuan Li
Journal:  Cancer Microenviron       Date:  2012-07-26

7.  Immunomodulatory effects of alpha interferon and thymostimulin in patients with neoplasias.

Authors:  I Munno; M Marinaro; A Gesario; B Cannuscio; Y Michel; E Paulling
Journal:  Clin Diagn Lab Immunol       Date:  1995-07

8.  Impaired cytokine production in whole blood cell cultures of patients with gynaecological carcinomas in different clinical stages.

Authors:  U Elsässer-Beile; S von Kleist; W Sauther; H Gallati; J S Mönting
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

9.  Interactions between rnacrophage cytokines and eicosanoids in expression of antitumour activity.

Authors:  S Ben-Efraim
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.